絞り込み

16633

広告

宇宙ビジネス シニア人材をベンチャー企業に!

宇宙ビジネス分野のベンチャー企業に、JAXA=宇宙航空研究開発機構などのシニア人材を引き合わせる取り組みがこの秋から始まります。経済産業省が主導し、日本の宇宙産...

  1. タイ:プラごみ誤飲 ジュゴンの赤ちゃん死...
  2. 優生社会を問う:新型出生前診断 利益大き...
  3. 安定狭心症患者に対する鍼治療のRCT (...
  4. 咳嗽診療、どこから「本気」を出す? (日...

ニュース一覧

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

著者 Heuser M , Gabdoulline R , Löffeld P , Dobbernack V , Kreimeyer H , Pankratz M , Flintrop M , Liebich A , Klesse S , Panagiota V , Stadler M , Wichmann M , Shahswar R , Platzbecker U , Thiede C , Schroeder T , Kobbe G , Geffers R , Schlegelberger B , Göhr
Ann Hematol.2017 Jun 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (12view , 0users)

Full Text Sources

Medical

Miscellaneous

We integrated molecular data with available prognostic factors in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) from MDS to evaluate their impact on prognosis. Three hundred four patients were sequenced for mutations in 54 genes. We used a Cox multivariate model and competing risk analysis with internal and cross validation to identify factors prognostic of overall survival (OS), cumulative incidence of relapse (CIR), and non-relapse mortality (NRM). In multivariate analysis, mutated NRAS, U2AF1, IDH2, and TP53 and/or a complex karyotype were significant prognostic markers for OS besides age above 60 years, remission status, IPSS-R cytogenetic risk, HCT-CI > 2 and female donor sex. Mutated NRAS, IDH1, EZH2, and TP53 and/or a complex karyotype were genetic aberrations with prognostic impact on CIR. No molecular markers were associated with the risk of NRM. The inclusion of molecular information results in better risk prediction models for OS and CIR when assessed by the Akaike information criterion. Internal cross validation confirmed the robustness of our comprehensive risk model. In summary, we propose to combine molecular, cytogenetic, and patient- and transplantation-associated risk factors into a comprehensive risk model to provide personalized predictions of outcome after alloHCT.
PMID: 28612220 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード